Drugs in the Pipeline Novel Factor XI Inhibitor Fast Tracked for Thrombosis Associated With Cancer Publish Date July 11, 2022 Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
